{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:49:24Z","timestamp":1794242964788,"version":"4.9.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T00:00:00Z","timestamp":1535673600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.81528014"],"award-info":[{"award-number":["No.81528014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s40618-018-0939-4","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T07:20:54Z","timestamp":1535700054000},"page":"443-451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Magnetic resonance spectroscopy may serve as a presurgical predictor of somatostatin analog therapy response in patients with growth hormone-secreting pituitary macroadenomas"],"prefix":"10.1007","volume":"42","author":[{"given":"J.","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,31]]},"reference":[{"issue":"1","key":"939_CR1","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1210\/er.2002-0022","volume":"25","author":"A Colao","year":"2004","unstructured":"Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25(1):102\u2013152. \n                    https:\/\/doi.org\/10.1210\/er.2002-0022","journal-title":"Endocr Rev"},{"key":"939_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1750-1172-3-17","volume":"3","author":"P Chanson","year":"2008","unstructured":"Chanson P, Salenave S (2008) Acromegaly. Orphanet J Rare Dis 3:17. \n                    https:\/\/doi.org\/10.1186\/1750-1172-3-17","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"939_CR3","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1210\/jc.2008-2421","volume":"94","author":"S Melmed","year":"2009","unstructured":"Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A, Acromegaly Consensus G (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94(5):1509\u20131517. \n                    https:\/\/doi.org\/10.1210\/jc.2008-2421","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"939_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/cen.12731","volume":"83","author":"M Puig Domingo","year":"2015","unstructured":"Puig Domingo M (2015) Treatment of acromegaly in the era of personalized and predictive medicine. Clin Endocrinol (Oxf) 83(1):3\u201314. \n                    https:\/\/doi.org\/10.1111\/cen.12731","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"939_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1530\/eje.1.01863","volume":"152","author":"P Nomikos","year":"2005","unstructured":"Nomikos P, Buchfelder M, Fahlbusch R (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical \u2018cure\u2019. Eur J Endocrinol 152(3):379\u2013387. \n                    https:\/\/doi.org\/10.1530\/eje.1.01863","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"939_CR6","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1365-2265.2007.02825.x","volume":"66","author":"M Mercado","year":"2007","unstructured":"Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, Patocs A, Petersenn S, Podoba J, Safari M, Wardlaw J, Group SBS (2007) A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 66(6):859\u2013868. \n                    https:\/\/doi.org\/10.1111\/j.1365-2265.2007.02825.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"939_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s12020-014-0383-y","volume":"49","author":"K Kiseljak-Vassiliades","year":"2015","unstructured":"Kiseljak-Vassiliades K, Carlson NE, Borges MT, Kleinschmidt-DeMasters BK, Lillehei KO, Kerr JM, Wierman ME (2015) Growth hormone tumor histological subtypes predict response to surgical and medical therapy. Endocrine 49(1):231\u2013241. \n                    https:\/\/doi.org\/10.1007\/s12020-014-0383-y","journal-title":"Endocrine"},{"issue":"1","key":"939_CR8","doi-asserted-by":"publisher","first-page":"E66","DOI":"10.1210\/jc.2012-2609","volume":"98","author":"F Gatto","year":"2013","unstructured":"Gatto F, Feelders RA, van der Pas R, Kros JM, Waaijers M, Sprij-Mooij D, Neggers SJ, van der Lelij AJ, Minuto F, Lamberts SW, de Herder WW, Ferone D, Hofland LJ (2013) Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J Clin Endocrinol Metab 98(1):E66\u2013E71. \n                    https:\/\/doi.org\/10.1210\/jc.2012-2609","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"939_CR9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1530\/EJE-14-0249","volume":"171","author":"SL Fougner","year":"2014","unstructured":"Fougner SL, Bollerslev J, Svartberg J, Oksnes M, Cooper J, Carlsen SM (2014) Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial. Eur J Endocrinol 171(2):229\u2013235. \n                    https:\/\/doi.org\/10.1530\/EJE-14-0249","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"939_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4103\/0022-3859.62421","volume":"56","author":"TR Bandgar","year":"2010","unstructured":"Bandgar TR, Sarathi V, Shivane V, Bansode N, Menon PS, Shah NS (2010) The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly. J Postgrad Med 56(1):7\u201311. \n                    https:\/\/doi.org\/10.4103\/0022-3859.62421","journal-title":"J Postgrad Med"},{"issue":"6","key":"939_CR11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1055\/s-2008-1065339","volume":"40","author":"I Halperin","year":"2008","unstructured":"Halperin I, Nicolau J, Casamitjana R, Sesmilo G, Serra-Prat M, Palomera E, Puig-Domingo M (2008) A short acute octreotide test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients. Hormone Metab Res 40(6):422\u2013426. \n                    https:\/\/doi.org\/10.1055\/s-2008-1065339","journal-title":"Hormone Metab Res"},{"issue":"1","key":"939_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1530\/eje.1.01935","volume":"153","author":"WW Herder de","year":"2005","unstructured":"de Herder WW, Taal HR, Uitterlinden P, Feelders RA, Janssen JA, van der Lely AJ (2005) Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. Eur J Endocrinol 153(1):67\u201371. \n                    https:\/\/doi.org\/10.1530\/eje.1.01935","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"939_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1530\/eje.1.02073","volume":"154","author":"A Pokrajac","year":"2006","unstructured":"Pokrajac A, Claridge AG, Shakoor SK, Trainer PJ (2006) The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly. Eur J Endocrinol 154(2):267\u2013274. \n                    https:\/\/doi.org\/10.1530\/eje.1.02073","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"939_CR14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1365-2265.2011.04286.x","volume":"77","author":"A Heck","year":"2012","unstructured":"Heck A, Ringstad G, Fougner SL, Casar-Borota O, Nome T, Ramm-Pettersen J, Bollerslev J (2012) Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol (Oxf) 77(1):72\u201378. \n                    https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04286.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"939_CR15","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1210\/jc.2010-0573","volume":"95","author":"M Puig-Domingo","year":"2010","unstructured":"Puig-Domingo M, Resmini E, Gomez-Anson B, Nicolau J, Mora M, Palomera E, Marti C, Halperin I, Webb SM (2010) Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J Clin Endocrinol Metab 95(11):4973\u20134978. \n                    https:\/\/doi.org\/10.1210\/jc.2010-0573","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"939_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s12020-015-0766-8","volume":"52","author":"A Heck","year":"2016","unstructured":"Heck A, Emblem KE, Casar-Borota O, Bollerslev J, Ringstad G (2016) Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine 52(2):333\u2013343. \n                    https:\/\/doi.org\/10.1007\/s12020-015-0766-8","journal-title":"Endocrine"},{"issue":"3","key":"939_CR17","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1148\/radiol.13130531","volume":"270","author":"G Oz","year":"2014","unstructured":"Oz G, Alger JR, Barker PB, Bartha R, Bizzi A, Boesch C, Bolan PJ, Brindle KM, Cudalbu C, Dincer A, Dydak U, Emir UE, Frahm J, Gonzalez RG, Gruber S, Gruetter R, Gupta RK, Heerschap A, Henning A, Hetherington HP, Howe FA, Huppi PS, Hurd RE, Kantarci K, Klomp DW, Kreis R, Kruiskamp MJ, Leach MO, Lin AP, Luijten PR, Marjanska M, Maudsley AA, Meyerhoff DJ, Mountford CE, Nelson SJ, Pamir MN, Pan JW, Peet AC, Poptani H, Posse S, Pouwels PJ, Ratai EM, Ross BD, Scheenen TW, Schuster C, Smith IC, Soher BJ, Tkac I, Vigneron DB, Kauppinen RA, Group MRSC (2014) Clinical proton MR spectroscopy in central nervous system disorders. Radiology 270(3):658\u2013679. \n                    https:\/\/doi.org\/10.1148\/radiol.13130531","journal-title":"Radiology"},{"issue":"8","key":"939_CR18","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1007\/s11547-013-0371-y","volume":"119","author":"A Costanzo Di","year":"2014","unstructured":"Di Costanzo A, Scarabino T, Trojsi F, Popolizio T, Bonavita S, de Cristofaro M, Conforti R, Cristofano A, Colonnese C, Salvolini U, Tedeschi G (2014) Recurrent glioblastoma multiforme versus radiation injury: a multiparametric 3-T MR approach. Radiol Med (Torino) 119(8):616\u2013624. \n                    https:\/\/doi.org\/10.1007\/s11547-013-0371-y","journal-title":"Radiol Med (Torino)"},{"issue":"10","key":"939_CR19","first-page":"1989","volume":"24","author":"M Law","year":"2003","unstructured":"Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S, Knopp EA, Zagzag D (2003) Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Am J Neuroradiol 24(10):1989\u20131998","journal-title":"Am J Neuroradiol"},{"issue":"1","key":"939_CR20","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1093\/neuonc\/nov097","volume":"18","author":"S Bluml","year":"2016","unstructured":"Bluml S, Margol AS, Sposto R, Kennedy RJ, Robison NJ, Vali M, Hung LT, Muthugounder S, Finlay JL, Erdreich-Epstein A, Gilles FH, Judkins AR, Krieger MD, Dhall G, Nelson MD, Asgharzadeh S (2016) Molecular subgroups of medulloblastoma identification using noninvasive magnetic resonance spectroscopy. Neuro-oncology 18(1):126\u2013131. \n                    https:\/\/doi.org\/10.1093\/neuonc\/nov097","journal-title":"Neuro-oncology"},{"issue":"2","key":"939_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11060-008-9698-y","volume":"91","author":"MF Chernov","year":"2009","unstructured":"Chernov MF, Kawamata T, Amano K, Ono Y, Suzuki T, Nakamura R, Muragaki Y, Iseki H, Kubo O, Hori T, Takakura K (2009) Possible role of single-voxel (1)H-MRS in differential diagnosis of suprasellar tumors. J Neurooncol 91(2):191\u2013198. \n                    https:\/\/doi.org\/10.1007\/s11060-008-9698-y","journal-title":"J Neurooncol"},{"issue":"4","key":"939_CR22","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/j.1365-2265.2004.02003.x","volume":"60","author":"M Alba","year":"2004","unstructured":"Alba M, Hall CM, Whatmore AJ, Clayton PE, Price DA, Salvatori R (2004) Variability in anterior pituitary size within members of a family with GH deficiency due to a new splice mutation in the GHRH receptor gene. Clin Endocrinol (Oxf) 60(4):470\u2013475. \n                    https:\/\/doi.org\/10.1111\/j.1365-2265.2004.02003.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"939_CR23","first-page":"610","volume":"33","author":"E Knosp","year":"1993","unstructured":"Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33(4):610\u2013617 (discussion 617\u2013618)","journal-title":"Neurosurgery"},{"issue":"1","key":"939_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1017\/S0317167100025944","volume":"3","author":"E Horvath","year":"1976","unstructured":"Horvath E, Kovacs K (1976) Ultrastructural classification of pituitary adenomas. Can J Neurol Sci 3(1):9\u201321","journal-title":"Can J Neurol Sci"},{"issue":"1","key":"939_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1365-2265.2011.04163.x","volume":"76","author":"SL Fougner","year":"2012","unstructured":"Fougner SL, Casar-Borota O, Heck A, Berg JP, Bollerslev J (2012) Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clin Endocrinol (Oxf) 76(1):96\u2013102. \n                    https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04163.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"939_CR26","doi-asserted-by":"publisher","first-page":"6290","DOI":"10.1210\/jc.2005-0998","volume":"90","author":"S Bhayana","year":"2005","unstructured":"Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S (2005) The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 90(11):6290\u20136295. \n                    https:\/\/doi.org\/10.1210\/jc.2005-0998","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"939_CR27","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1365-2265.2007.03065.x","volume":"68","author":"SL Fougner","year":"2008","unstructured":"Fougner SL, Borota OC, Berg JP, Hald JK, Ramm-Pettersen J, Bollerslev J (2008) The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin Endocrinol (Oxf) 68(3):458\u2013465. \n                    https:\/\/doi.org\/10.1111\/j.1365-2265.2007.03065.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"939_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3275\/8305","volume":"36","author":"LE Wildemberg","year":"2013","unstructured":"Wildemberg LE, Neto LV, Costa DF, Nasciuti LE, Takiya CM, Alves LM, Rebora A, Minuto F, Ferone D, Gadelha MR (2013) Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. J Endocrinol Invest 36(1):38\u201343. \n                    https:\/\/doi.org\/10.3275\/8305","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"939_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1530\/EJE-07-0562","volume":"158","author":"GF Taboada","year":"2008","unstructured":"Taboada GF, Luque RM, Neto LV, Machado Ede O, Sbaffi BC, Domingues RC, Marcondes JB, Chimelli LM, Fontes R, Niemeyer P, de Carvalho DP, Kineman RD, Gadelha MR (2008) Quantitative analysis of somatostatin receptor subtypes (1\u20135) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol 158(3):295\u2013303. \n                    https:\/\/doi.org\/10.1530\/EJE-07-0562","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"939_CR30","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1530\/EJE-13-0349","volume":"169","author":"L Kasuki","year":"2013","unstructured":"Kasuki L, Wildemberg LE, Neto LV, Marcondes J, Takiya CM, Gadelha MR (2013) Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern. Eur J Endocrinol 169(2):217\u2013223. \n                    https:\/\/doi.org\/10.1530\/EJE-13-0349","journal-title":"Eur J Endocrinol"},{"key":"939_CR31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.mce.2015.09.016","volume":"417","author":"K Kiseljak-Vassiliades","year":"2015","unstructured":"Kiseljak-Vassiliades K, Xu M, Mills TS, Smith EE, Silveira LJ, Lillehei KO, Kerr JM, Kleinschmidt-DeMasters BK, Wierman ME (2015) Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors. Mol Cell Endocrinol 417:73\u201383. \n                    https:\/\/doi.org\/10.1016\/j.mce.2015.09.016","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"939_CR32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.crad.2008.07.002","volume":"64","author":"DP Soares","year":"2009","unstructured":"Soares DP, Law M (2009) Magnetic resonance spectroscopy of the brain: review of metabolites and clinical applications. Clin Radiol 64(1):12\u201321. \n                    https:\/\/doi.org\/10.1016\/j.crad.2008.07.002","journal-title":"Clin Radiol"},{"issue":"5","key":"939_CR33","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s002340050894","volume":"42","author":"T Tamiya","year":"2000","unstructured":"Tamiya T, Kinoshita K, Ono Y, Matsumoto K, Furuta T, Ohmoto T (2000) Proton magnetic resonance spectroscopy reflects cellular proliferative activity in astrocytomas. Neuroradiology 42(5):333\u2013338","journal-title":"Neuroradiology"},{"issue":"3","key":"939_CR34","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1148\/radiol.13121856","volume":"267","author":"PA Baltzer","year":"2013","unstructured":"Baltzer PA, Dietzel M (2013) Breast lesions: diagnosis by using proton MR spectroscopy at 1.5 and 3.0 T\u2014systematic review and meta-analysis. Radiology 267(3):735\u2013746. \n                    https:\/\/doi.org\/10.1148\/radiol.13121856","journal-title":"Radiology"},{"issue":"1","key":"939_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00345-014-1272-y","volume":"33","author":"S Sevcenco","year":"2015","unstructured":"Sevcenco S, KrSSASsk M, Javor D, Ponhold L, Kuehhas FE, Fajkovic H, Haitel A, Shariat SF, Baltzer PA (2015) Diagnosis of renal tumors by in vivo proton magnetic resonance spectroscopy. World J Urol 33(1):17\u201323. \n                    https:\/\/doi.org\/10.1007\/s00345-014-1272-y","journal-title":"World J Urol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-018-0939-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-018-0939-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-018-0939-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T19:08:00Z","timestamp":1568747280000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-018-0939-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,31]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["939"],"URL":"https:\/\/doi.org\/10.1007\/s40618-018-0939-4","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,31]]},"assertion":[{"value":"16 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}